Marine Microbial Metabolites: A new wave of drugs for Combating Antimicrobial Resistance

Venkat Abhiram Earny; Venkatesh Kamath; Anuraag Muralidharan; Vandana K E; Kanav Khera

doi:10.52711/0974-360X.2021.00414

Research Journal of Pharmacy and Technology

ISSN

0974-360X (Online)
0974-3618 (Print)

Submit Article

Marine Microbial Metabolites: A new wave of drugs for Combating Antimicrobial Resistance

Author(s): Venkat Abhiram Earny, Venkatesh Kamath, Anuraag Muralidharan, Vandana K E, Kanav Khera

Email(s): venkatesh.kamath@manipal.edu

DOI: 10.52711/0974-360X.2021.00414

Address: Venkat Abhiram Earny1, Venkatesh Kamath1*, Anuraag Muralidharan1, Vandana K E2, Kanav Khera3
1Department of Pharmaceutical Biotechnology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal – 576104.
2Department of Microbiology, Kasturba Medical College, Manipal Academy of Higher Education, Manipal – 576104.
3Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal – 576104.
*Corresponding Author

Published In: Volume - 14, Issue - 4, Year - 2021

View HTML

View PDF

ABSTRACT:
The steady increase in the emergence of multidrug-resistant bacteria amongst medical centers, environment, animals, and food is of major concern for health care professionals. Most of the currently used mainline antibacterial drugs were discovered during the golden era of antibiotic discovery (1950-60). During this period, many natural, semi-synthetic, and synthetic molecules were screened for their antimicrobial potential against a spectrum of clinical pathogens. Nevertheless, there was a gap of forty long years until the release of a newer class of antibiotics in the market. It is very vital to develop an integrated approach to combat antimicrobial resistance. There has been a paradigm shift in the field of marine drug discovery in the last two decades. Bioactive metabolites derived from the marine ecosystem are known to exhibit a wide array of pharmacological activity than the terrestrial source. Among all marine organisms, secondary metabolites derived from microbes are the most underexplored natural source. Screening of marine microbes for various antimicrobial molecules has become a noteworthy trend in marine drug discovery and provides a ray of hope for combating antimicrobial resistance.

Keywords:

Cite this article:
Venkat Abhiram Earny, Venkatesh Kamath, Anuraag Muralidharan, Vandana K E, Kanav Khera. Marine Microbial Metabolites: A new wave of drugs for Combating Antimicrobial Resistance. Research Journal of Pharmacy and Technology. 2021; 14(4):2348-2. doi: 10.52711/0974-360X.2021.00414

Cite(Electronic):
Venkat Abhiram Earny, Venkatesh Kamath, Anuraag Muralidharan, Vandana K E, Kanav Khera. Marine Microbial Metabolites: A new wave of drugs for Combating Antimicrobial Resistance. Research Journal of Pharmacy and Technology. 2021; 14(4):2348-2. doi: 10.52711/0974-360X.2021.00414 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2021-14-4-90

REFERENCES:

1. Poole, K. (2004). Resistance to β-lactam antibiotics. Cellular and Molecular Life Sciences, 61(17). https://doi.org/10.1007/s00018-004-4060-9.

2. Frost, L. S., Leplae, R., Summers, A. O., and Toussaint, A. (2005). Mobile genetic elements: the agents of open source evolution. Nature Reviews Microbiology, 3(9), 722–732. https://doi.org/10.1038/nrmicro1235.

3. Niell OJ (2014). Antimicrobial Resistance: Tackling a crisis for the health and wealth and nations. https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf

4. Karanika, S., Karantanos, T., Arvanitis, M., Grigoras, C., and Mylonakis, E. (2016). Fecal Colonization with Extended-spectrum Beta-lactamase producing Enterobacteriaceae and Risk Factors Among Healthy Individuals: A Systematic Review and Metaanalysis. Clinical Infectious Diseases, 63(3), 310–318.https://doi.org/10.1093/cid/ciw283.

5. Luepke, K. H., Suda, K. J., Boucher, H., Russo, R. L., Bonney, M. W., Hunt, T. D., and Mohr, J. F., III. (2016). Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 37(1), 71–84. https://doi.org/10.1002/phar.1868.

6. WHO Global Strategy for Containment of Antimicrobial Resistance (2001). https://www.who.int/drugresistance/WHO_Global_Strategy_English.pdf

7. Tenover, F. C. (2006). Mechanisms of Antimicrobial Resistance in Bacteria. The American Journal of Medicine, 119(6), S3–S10. https://doi.org/10.1016/j.amjmed.2006.03.011.

8. Martinez, J. L., Fajardo, A., Garmendia, L., Hernandez, A., Linares, J. F., Martínez-Solano, L., and Sánchez, M. B. (2009). A global view of antibiotic resistance. FEMS Microbiology Reviews, 33(1), 44–65. https://doi.org/10.1111/j.1574-6976.2008.00142.

9. Andersson, D. I., and Hughes, D. (2010). Antibiotic resistance and its cost: is it possible to reverse resistance? Nature Reviews Microbiology, 8(4), 260–271. https://doi.org/10.1038/nrmicro2319

10. Burke, J. P. (2003). Infection Control — A Problem for Patient Safety. New England Journal of Medicine, 348(7), 651–656. https://doi.org/10.1056/nejmhpr020557

11. Ventola, C.L., 2015. The antibiotic resistance crisis: part 1: causes and threats. Pharmacy and therapeutics, 40(4), p.277.

12. Global Health- India (2019). https://www.cdc.gov/globalhealth/countries/india/pdf/India-Factsheet-p.pdf

13. Tacconelli, E., Carrara, E., Savoldi, A., Harbarth, S., Mendelson, M., Monnet, D. L., Pulcini, C., Kahlmeter, G., Kluytmans, J., Carmeli, Y., Ouellette, M., Outterson, K., Patel, J., Cavaleri, M., Cox, E. M., Houchens, C. R., Grayson, M. L., Hansen, P., Singh, N., Zorzet, A. (2018). Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. The Lancet Infectious Diseases, 18(3), 318–327. https://doi.org/10.1016/s1473-3099(17)30753-3

14. Antimicrobial resistance on global surveillance (2014). https://apps.who.int/iris/bitstream/handle/10665/112642/9789241564748_eng.pdf?sequence=1

15. Van Boeckel, T. P., Gandra, S., Ashok, A., Caudron, Q., Grenfell, B. T., Levin, S. A., and Laxminarayan, R. (2014). Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. The Lancet Infectious Diseases, 14(8), 742–750. https://doi.org/10.1016/s1473-3099(14)70780-7

16. McGettigan, P., Roderick, P., Kadam, A., and Pollock, A. M. (2017). Access, Watch, and Reserve antibiotics in India: challenges for WHO stewardship. The Lancet Global Health, 5(11), e1075–e1076. https://doi.org/10.1016/s2214-109x(17)30365-0

17. Multidrug resistant (or antimicrobial-resistant) pathogens - alternatives to new antibiotics? (2017). Swiss Medical Weekly, 147(4748). https://doi.org/10.4414/smw.2017.14553

18. How Much Water is there on Earth? (2019). https://www.usgs.gov/special-topic/water-science-school/science/how-much-water-there-earth?qt-science_center_objects=0#qt-science_center_objects

19. Kleigrewe, K., Gerwick, L., Sherman, D. H., and Gerwick, W. H. (2016). Unique marine derived cyanobacterial biosynthetic genes for chemical diversity. Natural Product Reports, 33(2), 348–364. https://doi.org/10.1039/c5np00097a

20. Martins A., Vieira, H., Gaspar H., and Santos, S. (2014). Marketed Marine Natural Products in the Pharmaceutical and Cosmeceutical Industries: Tips for Success. Marine Drugs, 12(2), 1066–1101. https://doi.org/10.3390/md12021066

21. Trindade M., van Zyl, L. J., Navarro-Fernández, J., and Abd Elrazak, A. (2015). Targeted metagenomics as a tool to tap into marine natural product diversity for the discovery and production of drug candidates. Frontiers in Microbiology, 6. https://doi.org/10.3389/fmicb.2015.00890

22. Skropeta D., and Wei, L. (2014). Recent advances in deep-sea natural products. Nat. Prod. Rep., 31(8), 999–1025. https://doi.org/10.1039/c3np70118b

23. Shinde, P., Banerjee, P., and Mandhare A. (2019). Marine natural products as source of new drugs: a patent review (2015–2018). Expert Opinion on Therapeutic Patents, 29(4), 283–309. https://doi.org/10.1080/13543776.2019.1598972

24. Rajivgandhi G., Vijayan, R., Kannan, M., Santhanakrishnan, M., and Manoharan, N. (2016). Molecular characterization and antibacterial effect of endophytic actinomycetes Nocardiopsis sp. GRG1 (KT235640) from brown algae against MDR strains of uropathogens. Bioactive Materials, 1(2), 140–150. https://doi.org/10.1016/j.bioactmat.2016.11.002

25. Rajivgandhi G., Ramachandran, G., Maruthupandy M., Vaseeharan B., and Manoharan, N. (2019). Molecular identification and structural characterization of marine endophytic actinomycetes Nocardiopsis sp. GRG 2 (KT 235641) and its antibacterial efficacy against isolated ESBL producing bacteria. Microbial Pathogenesis, 126, 138–148. https://doi.org/10.1016/j.micpath.2018.10.014

26. Hamed Norouzi, Abolghasem Danesh, Mojtaba Mohseni, and Mohammad Rabbani khorasgani. (2018). Marine Actinomycetes with Probiotic Potential and Bioactivity Against Multidrug-resistant Bacteria. International Journal of Molecular and Cellular Medicine, 7(1). https://doi.org/10.22088/IJMCM.BUMS.7.1.44

27. Al-Dhabi, N. A., Mohammed Ghilan, A.K., Esmail, G. A., Valan Arasu, M., Duraipandiyan V., and Ponmurugan K. (2019). Bioactivity assessment of the Saudi Arabian Marine Streptomyces sp. Al-Dhabi-90, metabolic profiling and its in vitro inhibitory property against multidrug resistant and extended-spectrum beta-lactamase clinical bacterial pathogens. Journal of Infection and Public Health, 12(4), 549–556. https://doi.org/10.1016/j.jiph.2019.01.065

28. Kiran GS, Priyadharsini S, Sajayan A, Ravindran A, Selvin J. An antibiotic agent pyrrolo[1,2- a ]pyrazine-1,4-dione,hexahydro isolated from a marine bacteria Bacillus tequilensis MSI45 effectively controls multi-drug resistant Staphylococcus aureus. RSC Adv. 2018;8(32):17837–46.

29. Rajivgandhi, G., Muneeswaran, T., Maruthupandy, M., Ramakritinan, C. M., Saravanan, K., Ravikumar, V., and Manoharan, N. (2018). Antibacterial and anticancer potential of marine endophytic actinomycetes Streptomyces coeruleorubidus GRG 4 (KY457708) compound against colistin resistant uropathogens and A549 lung cancer cells. Microbial Pathogenesis, 125, 325–335. https://doi.org/10.1016/j.micpath.2018.09.025

30. Tuin, A. W., Grotenbreg, G. M., Spalburg, E., de Neeling, A. J., Mars Groenendijk, R. H., van der Marel, G. A. Overhand, M. (2009). Structural and biological evaluation of some loloatin C analogues. Bioorganic and Medicinal Chemistry, 17(17), 6233–6240. https://doi.org/10.1016/j.bmc.2009.07.049

31. Machado, H., Mansson, M., and Gram, L. (2014). Draft Genome Sequence of Photobacterium halotolerans S2753, Producer of Bioactive Secondary Metabolites. Genome Announcements, 2(3). https://doi.org/10.1128/genomea.00535-14

32. Hu, Y., Phelan, V., Ntai, I., Farnet, C. M., Zazopoulos, E., and Bachmann, B. O. (2007). Benzodiazepine Biosynthesis in Streptomyces refuineus. Chemistry and Biology, 14(6), 691–701. https://doi.org/10.1016/j.chembiol.2007.05.009

33. Li, D., Carr, G., Zhang, Y., Williams, D. E., Amlani, A., Bottriell, H., Andersen, R. J. (2011). Turnagainolides A and B, Cyclic Depsipeptides Produced in Culture by a Bacillus sp.: Isolation, Structure Elucidation, and Synthesis. Journal of Natural Products, 74(5), 1093–1099. https://doi.org/10.1021/np200033y

34. Engelhardt, K., Degnes, K. F., Kemmler, M., Bredholt, H., Fjaervik, E., Klinkenberg, G., Sletta, H., Ellingsen, T. E., and Zotchev, S. B. (2010). Production of a New Thiopeptide Antibiotic, TP-1161, by a Marine Nocardiopsis Species. Applied and Environmental Microbiology, 76(15), 4969–4976. https://doi.org/10.1128/aem.00741-10

35. Mada Triandala Sibero, Tao Zhou, Yasuhiro Igarashi, Ocky Karna Radjasa, Agus Sabdono, Agus Trianto, Tiara Ulfa Bachtiarini, Muhammad Syaifudien. (2020). Bahry Chromanone-type compounds from marine sponge-derived Daldinia eschscholtzii KJMT FP 4.1. Journal of Applied Pharmaceutical Science, 10(1), 1–7. https://doi.org/10.7324/japs.2020.101001